Clinical trial
Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by…
NCT00006244 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006244 |
|---|---|
| Title | Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma |
| Official title | Immunotherapy for Autologous/Syngeneic Peripheral Blood Stem Cell (PBSC) Transplant Patients as Treatment for Advanced Multiple Myeloma |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | melphalan, recombinant interferon alfa, aldesleukin, in vitro-treated peripheral blood stem cell transplantation |
| Enrollment | 36 |
| Start date | Feb 1, 2000 |
| Primary completion | Apr 1, 2016 |
| Completion | Apr 1, 2016 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: